Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
- blonca9
- 12 minutes ago
- 1 min read
He discusses learnings about durability, dosing, biomarkers, and more for this first-in-class target.











.png)

